Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Mark Talamonti

Concepts (682)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Pancreatic Neoplasms
84
2022
603
11.560
Why?
Pancreatectomy
35
2022
136
4.690
Why?
Psoriasis
14
2020
228
4.610
Why?
Adenocarcinoma
45
2019
1126
4.560
Why?
Pancreaticoduodenectomy
22
2020
73
3.610
Why?
Carcinoma, Pancreatic Ductal
21
2022
93
3.320
Why?
Dermatologic Agents
7
2019
70
2.710
Why?
HLA-C Antigens
3
2017
22
1.790
Why?
Aged
109
2021
17525
1.700
Why?
Laparoscopy
16
2019
675
1.630
Why?
Middle Aged
112
2021
24057
1.580
Why?
Liver Neoplasms
13
2021
636
1.540
Why?
Neoplasm Staging
33
2018
1882
1.460
Why?
Neuroendocrine Tumors
8
2014
86
1.430
Why?
Bile Duct Neoplasms
4
2021
60
1.380
Why?
Antibodies, Monoclonal
9
2018
1377
1.350
Why?
Humans
192
2022
80750
1.350
Why?
Antibodies, Monoclonal, Humanized
12
2021
900
1.270
Why?
Pancreatic Fistula
6
2020
13
1.250
Why?
Male
121
2021
39628
1.250
Why?
Postoperative Complications
18
2022
2094
1.250
Why?
Carcinoma
7
2012
426
1.230
Why?
Female
123
2021
42514
1.220
Why?
Biliary Tract Neoplasms
3
2012
29
1.160
Why?
Retrospective Studies
56
2022
7529
1.160
Why?
Treatment Outcome
48
2022
7550
1.100
Why?
Colorectal Neoplasms
12
2020
865
1.030
Why?
Deoxycytidine
10
2018
235
1.020
Why?
Ampulla of Vater
4
2014
22
0.990
Why?
Aged, 80 and over
37
2021
6231
0.950
Why?
Adult
62
2021
24668
0.900
Why?
Portal Vein
2
2021
115
0.880
Why?
Antineoplastic Combined Chemotherapy Protocols
14
2017
2325
0.870
Why?
Pancreatic Diseases
4
2020
46
0.870
Why?
Endosonography
3
2015
92
0.860
Why?
Neoadjuvant Therapy
11
2016
274
0.850
Why?
Venous Thromboembolism
2
2022
121
0.850
Why?
Rectal Neoplasms
5
2007
113
0.830
Why?
Pancreatic Cyst
5
2009
27
0.830
Why?
Survival Analysis
25
2017
1521
0.830
Why?
General Surgery
2
2022
215
0.800
Why?
Biological Therapy
1
2020
45
0.790
Why?
Organizational Innovation
2
2020
35
0.790
Why?
Stents
4
2021
355
0.770
Why?
Acrodermatitis
1
2019
3
0.760
Why?
Endovascular Procedures
1
2021
170
0.740
Why?
Societies, Medical
3
2020
565
0.730
Why?
Venous Thrombosis
1
2021
229
0.730
Why?
Diffusion of Innovation
1
2019
71
0.720
Why?
Severity of Illness Index
10
2021
1695
0.720
Why?
Stomach Neoplasms
5
2016
251
0.710
Why?
Hepatectomy
5
2022
149
0.710
Why?
Postoperative Hemorrhage
3
2017
43
0.700
Why?
Prognosis
26
2016
3539
0.700
Why?
CA-19-9 Antigen
3
2014
11
0.690
Why?
Drainage
3
2015
141
0.660
Why?
Cholangiocarcinoma
4
2021
49
0.660
Why?
Surgical Wound Infection
3
2015
177
0.660
Why?
Survival Rate
24
2018
1818
0.650
Why?
Lymph Node Excision
8
2016
197
0.650
Why?
Colonic Neoplasms
9
2021
537
0.630
Why?
Dermatitis, Atopic
2
2021
44
0.630
Why?
Thrombosis
1
2019
271
0.620
Why?
Length of Stay
8
2017
656
0.620
Why?
Adenocarcinoma, Mucinous
2
2007
41
0.610
Why?
Pancreatitis
5
2015
83
0.600
Why?
Preoperative Care
8
2017
388
0.600
Why?
Alleles
2
2017
1083
0.600
Why?
Education, Medical
1
2019
215
0.600
Why?
Learning
1
2019
255
0.590
Why?
Intestinal Neoplasms
2
2009
56
0.580
Why?
Embolization, Therapeutic
2
2014
205
0.570
Why?
Chemotherapy, Adjuvant
15
2017
446
0.560
Why?
Mass Screening
2
2015
594
0.560
Why?
Antimetabolites, Antineoplastic
6
2018
235
0.560
Why?
Mesenteric Veins
4
2021
33
0.550
Why?
Radiotherapy, Adjuvant
12
2018
286
0.550
Why?
Regional Health Planning
2
2014
13
0.550
Why?
Proportional Hazards Models
11
2017
829
0.540
Why?
Interleukin-17
3
2020
96
0.540
Why?
Registries
6
2017
654
0.540
Why?
Hepatic Artery
1
2014
76
0.530
Why?
Cohort Studies
11
2020
2587
0.520
Why?
Cornified Envelope Proline-Rich Proteins
1
2013
6
0.510
Why?
Surgery, Computer-Assisted
1
2015
98
0.510
Why?
Carcinoma, Papillary
4
2007
151
0.510
Why?
Risk Factors
21
2022
5142
0.510
Why?
Combined Modality Therapy
16
2016
1621
0.500
Why?
Patient Readmission
4
2017
293
0.500
Why?
Databases, Factual
10
2017
759
0.460
Why?
Early Detection of Cancer
2
2015
341
0.460
Why?
Barrett Esophagus
5
2018
91
0.450
Why?
Quality Indicators, Health Care
2
2010
132
0.450
Why?
United States
27
2018
6149
0.440
Why?
Safety-Based Drug Withdrawals
1
2011
2
0.440
Why?
Radiotherapy, Conformal
2
2011
87
0.430
Why?
Prospective Studies
9
2019
3933
0.430
Why?
Multivariate Analysis
9
2019
968
0.430
Why?
Lymph Nodes
7
2016
514
0.420
Why?
Carcinoma, Hepatocellular
3
2018
334
0.420
Why?
Esophageal Neoplasms
8
2018
303
0.410
Why?
Withholding Treatment
1
2011
109
0.400
Why?
Carcinoid Tumor
4
2002
41
0.400
Why?
SEER Program
3
2014
180
0.400
Why?
Health Care Costs
2
2017
229
0.390
Why?
Follow-Up Studies
16
2018
3575
0.380
Why?
Quality of Health Care
2
2010
367
0.380
Why?
Logistic Models
9
2020
1117
0.360
Why?
Intestine, Small
2
2009
297
0.360
Why?
Pancreas
7
2012
224
0.360
Why?
Neoplasm, Residual
2
2016
144
0.350
Why?
Endoscopy, Gastrointestinal
2
2018
150
0.350
Why?
Hospitals, Veterans
1
2007
17
0.340
Why?
Angiogenesis Inhibitors
1
2010
291
0.340
Why?
Young Adult
12
2021
5736
0.340
Why?
Hospital Bed Capacity
1
2007
19
0.340
Why?
Age Factors
5
2018
1800
0.330
Why?
Neoplasms
8
2022
2681
0.330
Why?
Hospitals
5
2019
213
0.330
Why?
Incidence
10
2022
1539
0.320
Why?
DNA-Binding Proteins
1
2013
1187
0.320
Why?
Cholangitis
1
2006
18
0.300
Why?
Patient Selection
4
2014
666
0.300
Why?
Hospital Costs
3
2017
99
0.300
Why?
Delivery of Health Care
1
2010
341
0.290
Why?
Diagnostic Techniques and Procedures
1
2005
25
0.290
Why?
Time Factors
9
2018
5158
0.290
Why?
Gastrectomy
2
2016
61
0.290
Why?
Disposable Equipment
2
2015
17
0.280
Why?
Risk Assessment
5
2019
2171
0.270
Why?
Hospitals, Community
3
2010
28
0.270
Why?
Gallbladder Neoplasms
2
2020
22
0.270
Why?
Insurance Claim Review
1
2004
37
0.260
Why?
Rectum
1
2004
152
0.250
Why?
Esophagectomy
3
2012
74
0.250
Why?
Liver Transplantation
3
2018
1241
0.250
Why?
Drug Administration Schedule
6
2017
932
0.250
Why?
Rectus Abdominis
2
2017
36
0.250
Why?
Chemoradiotherapy
3
2016
296
0.250
Why?
Benzoates
4
2007
46
0.240
Why?
Fluorouracil
9
2017
548
0.240
Why?
Mortality
1
2004
147
0.240
Why?
Cecal Neoplasms
1
2002
4
0.230
Why?
Diagnosis, Differential
6
2015
1497
0.230
Why?
Biliary Tract Diseases
1
2022
34
0.230
Why?
Ileal Neoplasms
1
2002
8
0.230
Why?
Chronic Disease
3
2020
940
0.230
Why?
Neoplasm Metastasis
5
2013
1038
0.230
Why?
Immunosuppressive Agents
3
2021
983
0.230
Why?
Anus Neoplasms
3
2011
41
0.230
Why?
Common Bile Duct Neoplasms
1
2001
6
0.230
Why?
Endoscopy, Digestive System
2
2012
66
0.220
Why?
Bile Ducts, Extrahepatic
2
2012
12
0.220
Why?
Italy
2
2020
102
0.220
Why?
Situs Inversus
1
2001
13
0.220
Why?
Chemoradiotherapy, Adjuvant
3
2018
34
0.220
Why?
Genotype
2
2017
1785
0.220
Why?
Algorithms
4
2018
1780
0.220
Why?
Eczema
1
2021
5
0.220
Why?
Gene Expression Regulation, Neoplastic
6
2010
1168
0.210
Why?
Palliative Care
5
2007
241
0.210
Why?
Sigmoidoscopy
1
2001
35
0.210
Why?
Tomography, X-Ray Computed
8
2017
2444
0.210
Why?
Anastomosis, Surgical
5
2016
286
0.210
Why?
Nurse Practitioners
1
2001
30
0.210
Why?
Thyroid Neoplasms
4
2020
374
0.210
Why?
Models, Theoretical
1
2004
478
0.210
Why?
Cystic Fibrosis Transmembrane Conductance Regulator
1
2020
67
0.210
Why?
Adolescent
12
2021
8710
0.200
Why?
Cell Cycle
3
2007
500
0.200
Why?
Drug Substitution
2
2018
28
0.200
Why?
Europe
2
2019
300
0.200
Why?
Genetic Markers
3
2017
470
0.200
Why?
Chemoembolization, Therapeutic
4
2009
31
0.200
Why?
Emergencies
1
2020
106
0.200
Why?
Drug Eruptions
1
2020
35
0.200
Why?
Gastrointestinal Neoplasms
3
2001
103
0.200
Why?
Colonic Polyps
2
2008
126
0.190
Why?
Personnel Selection
1
2020
52
0.190
Why?
Cancer Care Facilities
2
2010
26
0.190
Why?
Cystic Fibrosis
1
2020
121
0.190
Why?
Neoplasm Invasiveness
6
2012
517
0.190
Why?
Specialties, Surgical
1
2020
59
0.190
Why?
Lymphatic Metastasis
8
2008
466
0.190
Why?
Cell Proliferation
6
2008
1544
0.190
Why?
Fellowships and Scholarships
1
2020
96
0.190
Why?
Arachidonate 5-Lipoxygenase
3
2008
22
0.180
Why?
Interviews as Topic
1
2020
314
0.180
Why?
Kaplan-Meier Estimate
5
2018
847
0.180
Why?
User-Computer Interface
1
2020
184
0.180
Why?
Yttrium Radioisotopes
2
2009
29
0.180
Why?
Neoplasm Recurrence, Local
6
2014
1223
0.180
Why?
Propensity Score
4
2020
136
0.180
Why?
Adenoma
3
2008
232
0.180
Why?
Education, Medical, Continuing
2
2015
103
0.170
Why?
Carcinoma, Ductal, Breast
2
1997
154
0.170
Why?
Comorbidity
3
2021
919
0.170
Why?
Radiotherapy
4
2012
325
0.170
Why?
Thyroidectomy
3
2007
162
0.170
Why?
Reoperation
3
2017
571
0.170
Why?
Carcinoma in Situ
2
2005
52
0.170
Why?
Gene Expression Profiling
3
2018
1325
0.170
Why?
Gene Amplification
1
2018
128
0.170
Why?
Liver
2
2017
1199
0.170
Why?
Databases as Topic
2
2007
90
0.170
Why?
Stromal Cells
2
2015
119
0.160
Why?
Receptors, Calcitriol
1
2018
129
0.160
Why?
Laparotomy
1
2017
53
0.160
Why?
Evidence-Based Medicine
1
2020
423
0.160
Why?
Nuclear Proteins
2
1999
683
0.160
Why?
Receptors, Interleukin-17
1
2016
10
0.160
Why?
Predictive Value of Tests
5
2014
1622
0.160
Why?
Incidental Findings
1
2017
90
0.160
Why?
Abdominal Wall
1
2017
29
0.160
Why?
Dyslipidemias
1
2018
106
0.160
Why?
Pylorus
2
2007
22
0.160
Why?
Muscular Atrophy
1
2017
38
0.160
Why?
Longitudinal Studies
2
2018
950
0.160
Why?
Stomach
2
2012
109
0.160
Why?
Skin
2
2020
540
0.160
Why?
Proto-Oncogene Proteins pp60(c-src)
2
1993
12
0.150
Why?
Electric Impedance
1
2016
102
0.150
Why?
Vascular Surgical Procedures
1
2017
147
0.150
Why?
Antineoplastic Agents
4
2016
2281
0.150
Why?
Guideline Adherence
4
2017
216
0.150
Why?
Disease-Free Survival
4
2017
1183
0.150
Why?
Tetradecanoylphorbol Acetate
2
2006
137
0.150
Why?
Cell Line, Tumor
10
2018
2329
0.150
Why?
Gastroesophageal Reflux
2
2015
106
0.150
Why?
Mutation
3
2018
3768
0.140
Why?
Drug Resistance
1
2016
262
0.140
Why?
Lymphoma
2
2002
258
0.140
Why?
Benchmarking
2
2008
58
0.140
Why?
Academic Medical Centers
2
2007
356
0.140
Why?
Feasibility Studies
4
2016
721
0.140
Why?
Coronavirus Infections
1
2020
283
0.140
Why?
Pneumonia, Viral
1
2020
302
0.140
Why?
Cell Division
6
2007
705
0.140
Why?
Remission, Spontaneous
1
2014
52
0.130
Why?
Membrane Proteins
4
2005
1169
0.130
Why?
Cholecystectomy, Laparoscopic
1
2014
47
0.130
Why?
Herniorrhaphy
1
2015
71
0.130
Why?
Hernia, Inguinal
1
2015
64
0.130
Why?
Mitogen-Activated Protein Kinases
2
2005
220
0.130
Why?
Gene Frequency
1
2016
650
0.130
Why?
Genetic Predisposition to Disease
3
2018
2171
0.130
Why?
Operating Rooms
1
2014
119
0.130
Why?
Magnetic Resonance Imaging
4
2015
3089
0.120
Why?
Quality Improvement
1
2017
366
0.120
Why?
Neutropenia
2
2011
212
0.120
Why?
Cost-Benefit Analysis
3
2017
425
0.120
Why?
Trisaccharides
1
2012
12
0.120
Why?
Immunotherapy, Active
1
2012
15
0.120
Why?
Interleukin-23
1
2013
56
0.120
Why?
Internship and Residency
1
2022
920
0.120
Why?
Interleukin-12
1
2013
109
0.120
Why?
Urinary Bladder Neoplasms
2
1993
349
0.120
Why?
Hemorrhage
1
2014
236
0.120
Why?
Quality Control
1
2012
112
0.120
Why?
Radiopharmaceuticals
2
2012
157
0.120
Why?
Jaundice, Obstructive
1
2012
10
0.120
Why?
Gallbladder
1
2012
26
0.120
Why?
Arthritis, Psoriatic
1
2012
29
0.120
Why?
Adipocytes, White
1
2012
2
0.120
Why?
Ischemic Preconditioning
1
2012
37
0.110
Why?
Nausea
2
2011
169
0.110
Why?
Bile Ducts, Intrahepatic
1
2012
51
0.110
Why?
Electroporation
1
2012
56
0.110
Why?
Practice Guidelines as Topic
1
2020
1032
0.110
Why?
Serpins
1
2012
26
0.110
Why?
Organoplatinum Compounds
3
2017
95
0.110
Why?
Gene Deletion
1
2013
328
0.110
Why?
Leucovorin
3
2017
219
0.110
Why?
Ablation Techniques
1
2012
30
0.110
Why?
Protein-Tyrosine Kinases
2
1993
300
0.110
Why?
Nerve Growth Factors
1
2012
60
0.110
Why?
Spectrum Analysis
1
2012
120
0.110
Why?
Esophagus
1
2012
102
0.110
Why?
Sex Factors
4
2014
1020
0.110
Why?
Radiology, Interventional
1
2012
69
0.110
Why?
Ultrasonography, Interventional
1
2012
106
0.110
Why?
Lipoxygenase Inhibitors
2
2008
33
0.110
Why?
Microspheres
2
2009
89
0.110
Why?
Photochemotherapy
1
2012
93
0.110
Why?
Arteries
1
2012
176
0.110
Why?
Disease Progression
5
2018
1431
0.110
Why?
Cancer Vaccines
1
2012
152
0.110
Why?
Leukopenia
1
2011
65
0.110
Why?
Ileus
1
2011
13
0.110
Why?
Abdominal Abscess
1
2011
18
0.110
Why?
Camptothecin
3
2017
194
0.110
Why?
Proto-Oncogene Proteins p21(ras)
1
2012
140
0.110
Why?
Brachytherapy
1
2012
116
0.110
Why?
Clinical Trials as Topic
1
2016
1150
0.110
Why?
Appointments and Schedules
1
2011
35
0.100
Why?
Biopsy
5
2009
1123
0.100
Why?
Receptors, Leukotriene B4
2
2007
4
0.100
Why?
Endoscopy
2
2022
314
0.100
Why?
Chromosome Aberrations
1
2012
381
0.100
Why?
Methotrexate
1
2011
247
0.100
Why?
Treatment Failure
2
2009
281
0.100
Why?
Immunohistochemistry
9
2009
1725
0.100
Why?
Health Services Needs and Demand
1
2011
95
0.100
Why?
G2 Phase
2
2006
32
0.100
Why?
Intestinal Obstruction
1
2011
91
0.100
Why?
Mucin 5AC
1
2009
8
0.100
Why?
Mucin-2
1
2009
13
0.100
Why?
Cyclosporine
1
2011
241
0.100
Why?
Waiting Lists
1
2011
149
0.100
Why?
Mucin-1
1
2009
45
0.100
Why?
Pancreatic Ducts
2
1999
24
0.100
Why?
Learning Curve
2
2022
18
0.100
Why?
Spleen
1
2011
438
0.100
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2012
244
0.100
Why?
Sarcoma
2
2002
204
0.100
Why?
Pancreatitis, Chronic
1
2010
47
0.100
Why?
Adrenal Cortex Hormones
1
2021
253
0.100
Why?
Duodenal Neoplasms
1
2009
19
0.100
Why?
Safety
2
2010
157
0.090
Why?
Remission Induction
1
2011
707
0.090
Why?
Maximum Tolerated Dose
2
2010
269
0.090
Why?
Illinois
3
2015
450
0.090
Why?
Polymorphism, Genetic
1
2013
798
0.090
Why?
Vitamin D
3
2018
261
0.090
Why?
Hypertension
1
2018
1201
0.090
Why?
Breast Neoplasms
3
1999
2738
0.090
Why?
DNA Methylation
3
2010
585
0.090
Why?
Ischemia
1
2011
242
0.090
Why?
Radiotherapy Dosage
2
2011
481
0.090
Why?
Carcinoma, Acinar Cell
1
2008
11
0.090
Why?
S Phase
2
2007
61
0.090
Why?
Research Design
3
2009
566
0.090
Why?
Hepatocyte Nuclear Factor 1-beta
1
2008
34
0.090
Why?
Animals
11
2016
25816
0.090
Why?
Chicago
2
2020
1339
0.090
Why?
Socioeconomic Factors
2
2008
537
0.090
Why?
Neoplasms, Squamous Cell
1
2008
20
0.090
Why?
Esophagogastric Junction
1
2008
31
0.090
Why?
Gastroscopy
1
2007
22
0.090
Why?
Sentinel Lymph Node Biopsy
1
2008
55
0.090
Why?
Adenocarcinoma, Clear Cell
1
2008
59
0.090
Why?
Gastrointestinal Stromal Tumors
1
2007
22
0.090
Why?
Diagnostic Imaging
1
2012
448
0.080
Why?
Catheter Ablation
1
2010
217
0.080
Why?
Apoptosis
4
2008
1654
0.080
Why?
Leukotriene Antagonists
1
2007
25
0.080
Why?
Apigenin
1
2006
7
0.080
Why?
Hemothorax
1
1987
13
0.080
Why?
Referral and Consultation
1
2010
306
0.080
Why?
Stilbenes
1
2007
23
0.080
Why?
MicroRNAs
1
2012
509
0.080
Why?
Hospitals, Teaching
1
2007
113
0.080
Why?
Disease Models, Animal
2
2008
2186
0.080
Why?
Dose-Response Relationship, Drug
4
2006
1972
0.080
Why?
Adenoma, Islet Cell
2
2007
27
0.080
Why?
Quality Assurance, Health Care
1
2008
223
0.080
Why?
Mitosis
1
2006
147
0.080
Why?
Guidelines as Topic
1
2007
159
0.080
Why?
Bone Morphogenetic Proteins
1
2007
127
0.080
Why?
Leukotriene B4
1
2005
12
0.070
Why?
Depsipeptides
1
2006
29
0.070
Why?
Neoplasm Seeding
1
2005
17
0.070
Why?
Patient Compliance
1
2007
223
0.070
Why?
Ultrasonography
2
2012
656
0.070
Why?
Epithelium
1
2006
312
0.070
Why?
Surgical Flaps
1
2008
249
0.070
Why?
Cystadenocarcinoma
2
1995
12
0.070
Why?
Odds Ratio
1
2007
648
0.070
Why?
Postoperative Care
2
2017
206
0.070
Why?
Bariatric Surgery
1
2008
186
0.070
Why?
Cyclooxygenase 2
1
2005
99
0.070
Why?
Phosphorylation
4
2006
1099
0.070
Why?
Blotting, Western
4
2012
778
0.070
Why?
Reference Values
2
1999
656
0.070
Why?
Tissue Inhibitor of Metalloproteinase-1
1
2004
16
0.070
Why?
Proto-Oncogene Proteins c-bcl-2
2
2007
182
0.070
Why?
Antineoplastic Agents, Phytogenic
1
2007
284
0.070
Why?
Diagnostic Errors
1
2006
157
0.070
Why?
Actuarial Analysis
2
2002
66
0.070
Why?
Phosphatidylinositol 3-Kinases
1
2005
240
0.070
Why?
Drug Synergism
1
2005
305
0.070
Why?
Reconstructive Surgical Procedures
1
2008
262
0.070
Why?
Pilot Projects
2
2017
802
0.070
Why?
Infusions, Intra-Arterial
2
2008
27
0.070
Why?
Gene Expression Regulation, Enzymologic
1
2005
211
0.070
Why?
Fatal Outcome
1
2004
285
0.070
Why?
Melanoma
1
2008
430
0.060
Why?
Soft Tissue Neoplasms
1
2004
125
0.060
Why?
RNA, Messenger
4
2018
1936
0.060
Why?
Skin Neoplasms
1
2008
512
0.060
Why?
Demography
1
2004
159
0.060
Why?
Radiography
1
2005
806
0.060
Why?
Social Class
1
2004
122
0.060
Why?
Capillaries
1
2003
90
0.060
Why?
Protein Kinases
2
1996
207
0.060
Why?
Case-Control Studies
2
2006
1735
0.060
Why?
Cyclin A
3
2007
28
0.060
Why?
Hyperparathyroidism
1
2002
67
0.060
Why?
Heparin, Low-Molecular-Weight
1
2022
28
0.060
Why?
Parathyroid Neoplasms
1
2002
52
0.060
Why?
Colectomy
3
2008
174
0.060
Why?
Carcinoembryonic Antigen
2
1999
37
0.060
Why?
Parathyroidectomy
1
2002
73
0.060
Why?
Bile
1
2022
54
0.060
Why?
Immunoenzyme Techniques
3
2008
301
0.060
Why?
Cadherins
1
2002
147
0.060
Why?
Cardiac Surgical Procedures
1
1987
447
0.060
Why?
Regression Analysis
2
2017
591
0.060
Why?
Bone Neoplasms
1
2004
319
0.060
Why?
Biopsy, Needle
2
2009
234
0.060
Why?
Thymidylate Synthase
1
2001
13
0.060
Why?
Cholangiopancreatography, Endoscopic Retrograde
1
2001
59
0.050
Why?
Cell Cycle Proteins
2
2006
375
0.050
Why?
Outpatient Clinics, Hospital
1
2001
22
0.050
Why?
Credentialing
1
2001
15
0.050
Why?
Marketing of Health Services
1
2001
14
0.050
Why?
DNA, Neoplasm
2
2006
266
0.050
Why?
Midwestern United States
1
2001
74
0.050
Why?
Clinical Competence
2
2022
715
0.050
Why?
Cisplatin
3
2011
586
0.050
Why?
Biological Specimen Banks
1
2020
52
0.050
Why?
Dose-Response Relationship, Radiation
1
2000
190
0.050
Why?
Neovascularization, Pathologic
1
2002
337
0.050
Why?
Surgical Procedures, Operative
2
2011
167
0.050
Why?
Sequence Deletion
1
2020
206
0.050
Why?
Sensitivity and Specificity
2
2009
1943
0.050
Why?
Florida
1
2020
50
0.050
Why?
Leiomyomatosis
1
2000
12
0.050
Why?
Morbidity
1
2020
139
0.050
Why?
Pharyngeal Neoplasms
1
1999
13
0.050
Why?
Untranslated Regions
1
2019
19
0.050
Why?
Infusions, Intravenous
1
2000
434
0.050
Why?
Nuclear Matrix-Associated Proteins
1
1999
13
0.050
Why?
Bronchi
1
2020
227
0.050
Why?
Antigens, Nuclear
1
1999
25
0.050
Why?
Reagent Kits, Diagnostic
1
1999
36
0.050
Why?
ROC Curve
2
2014
736
0.050
Why?
Anticoagulants
1
2022
385
0.050
Why?
Adenomatous Polyposis Coli
1
1999
43
0.050
Why?
Open Reading Frames
1
2019
119
0.050
Why?
Congresses as Topic
1
2020
117
0.050
Why?
Immunoassay
1
1999
89
0.050
Why?
Steroids
1
2020
167
0.050
Why?
Genetic Counseling
1
1999
92
0.050
Why?
Tumor Suppressor Protein p53
1
2001
361
0.050
Why?
Program Evaluation
1
2020
287
0.040
Why?
Class II Phosphatidylinositol 3-Kinases
1
2018
8
0.040
Why?
Autoantigens
1
1999
129
0.040
Why?
Lymphoma, Non-Hodgkin
1
2020
256
0.040
Why?
Statistics, Nonparametric
2
2009
303
0.040
Why?
Chi-Square Distribution
2
2009
359
0.040
Why?
Intention to Treat Analysis
1
2018
67
0.040
Why?
Cryosurgery
1
1998
33
0.040
Why?
Flow Cytometry
3
2007
683
0.040
Why?
Receptor, Notch1
1
2018
81
0.040
Why?
Gastrointestinal Diseases
1
1999
143
0.040
Why?
Curriculum
1
2022
483
0.040
Why?
Tumor Cells, Cultured
3
2008
1039
0.040
Why?
Radiography, Abdominal
1
2017
68
0.040
Why?
Hernia, Ventral
1
2017
24
0.040
Why?
Neoplasms, Second Primary
1
2000
244
0.040
Why?
Prolactinoma
1
1997
8
0.040
Why?
Nucleic Acid Synthesis Inhibitors
2
2007
16
0.040
Why?
Blood Loss, Surgical
1
2017
106
0.040
Why?
Shock, Septic
1
2017
79
0.040
Why?
Atrophy
1
2017
75
0.040
Why?
Cyclin E
2
2007
27
0.040
Why?
Cyclin B
2
2006
16
0.040
Why?
Genetic Engineering
1
1997
108
0.040
Why?
Animals, Genetically Modified
1
1997
180
0.040
Why?
Clinical Trials, Phase II as Topic
1
1998
170
0.040
Why?
Breast Neoplasms, Male
1
1997
29
0.040
Why?
Blood Transfusion
1
2017
150
0.040
Why?
Reverse Transcriptase Polymerase Chain Reaction
3
2008
869
0.040
Why?
Serum Albumin
1
2017
132
0.040
Why?
Models, Economic
1
2017
60
0.040
Why?
Cyclin-Dependent Kinase Inhibitor p21
2
2007
73
0.040
Why?
Pituitary Neoplasms
1
1997
64
0.040
Why?
Body Composition
1
2016
65
0.040
Why?
Neoplasms, Multiple Primary
1
1997
101
0.040
Why?
Vascular Endothelial Growth Factor A
1
2018
374
0.040
Why?
Oligonucleotide Array Sequence Analysis
2
2010
679
0.040
Why?
Promoter Regions, Genetic
1
1999
918
0.040
Why?
Data Collection
1
2017
357
0.040
Why?
Molecular Sequence Data
4
2005
3051
0.040
Why?
Cystadenoma, Mucinous
1
1995
7
0.040
Why?
Cystadenoma, Serous
1
1995
15
0.040
Why?
Butadienes
2
2005
33
0.040
Why?
Drug Therapy, Combination
1
2018
907
0.040
Why?
RNA Helicases
1
1996
34
0.040
Why?
Flavonoids
2
2006
84
0.040
Why?
Mice
5
2012
10840
0.040
Why?
Genetic Heterogeneity
1
2015
60
0.040
Why?
Cost Control
1
2015
44
0.040
Why?
Genes, Tumor Suppressor
1
1996
157
0.040
Why?
Nitriles
2
2005
140
0.040
Why?
Keratin-19
1
2014
9
0.040
Why?
Mice, Nude
2
2008
764
0.030
Why?
Cystadenoma
1
1994
19
0.030
Why?
Polyethylene Glycols
1
2017
362
0.030
Why?
Inhibitor of Apoptosis Proteins
1
2014
33
0.030
Why?
Ki-67 Antigen
1
2014
57
0.030
Why?
Proton Pump Inhibitors
1
2015
33
0.030
Why?
Radiotherapy, Intensity-Modulated
1
2016
181
0.030
Why?
Neoplasm Regression, Spontaneous
1
2014
6
0.030
Why?
Proto-Oncogene Proteins c-kit
1
2014
79
0.030
Why?
Patient Care Planning
1
2015
80
0.030
Why?
Perioperative Care
1
2016
151
0.030
Why?
Clinical Trials, Phase III as Topic
1
2015
160
0.030
Why?
Pandemics
1
2020
603
0.030
Why?
Surgical Mesh
1
2015
85
0.030
Why?
Mastectomy
1
1996
222
0.030
Why?
Adipose Tissue
1
2016
238
0.030
Why?
Gene Expression
2
2015
1280
0.030
Why?
Postoperative Period
1
2014
295
0.030
Why?
Breast
1
1996
273
0.030
Why?
Double-Blind Method
1
2018
1798
0.030
Why?
Bone Density Conservation Agents
1
2014
46
0.030
Why?
DNA
2
2010
1252
0.030
Why?
Angiotensin-Converting Enzyme Inhibitors
1
2015
250
0.030
Why?
Phosphopyruvate Hydratase
1
1993
40
0.030
Why?
Mammography
1
1996
452
0.030
Why?
Body Mass Index
1
2016
740
0.030
Why?
Antigen-Antibody Complex
1
1993
87
0.030
Why?
Jejunostomy
1
2012
14
0.030
Why?
Gastric Emptying
1
2012
22
0.030
Why?
Ligation
1
2012
52
0.030
Why?
Blood Sedimentation
1
2012
14
0.030
Why?
Synovial Membrane
1
2012
27
0.030
Why?
Celiac Artery
1
2012
21
0.030
Why?
Population Surveillance
1
2014
220
0.030
Why?
Cell Transformation, Neoplastic
1
2015
405
0.030
Why?
Immunoblotting
1
1993
266
0.030
Why?
Analysis of Variance
1
2014
900
0.030
Why?
Bone Resorption
1
2012
42
0.030
Why?
Genetic Variation
1
2019
1322
0.030
Why?
Enteral Nutrition
1
2012
98
0.030
Why?
Rats
3
2005
3940
0.030
Why?
Matrix Metalloproteinase 2
1
2012
42
0.030
Why?
Rats, Sprague-Dawley
2
2005
1199
0.030
Why?
Cricetinae
2
2005
561
0.030
Why?
Matrix Metalloproteinase 9
1
2012
70
0.030
Why?
Adiposity
1
2012
67
0.030
Why?
Constriction, Pathologic
1
2012
201
0.030
Why?
Mitomycin
1
2011
31
0.030
Why?
C-Reactive Protein
1
2012
183
0.030
Why?
Anastomotic Leak
1
2012
101
0.030
Why?
Benzodiazepines
1
2011
62
0.030
Why?
Randomized Controlled Trials as Topic
1
2015
812
0.030
Why?
Real-Time Polymerase Chain Reaction
1
2012
266
0.030
Why?
Eye Proteins
1
2012
122
0.030
Why?
Genome-Wide Association Study
1
2018
1508
0.030
Why?
Validation Studies as Topic
1
2010
15
0.030
Why?
Intestinal Perforation
1
1990
34
0.030
Why?
Tissue Array Analysis
1
2010
120
0.020
Why?
Health Care Surveys
1
2011
275
0.020
Why?
Metaplasia
1
2009
36
0.020
Why?
Sphincterotomy, Endoscopic
1
2009
9
0.020
Why?
Forecasting
1
2011
306
0.020
Why?
Obesity
1
2016
919
0.020
Why?
Polymorphism, Single Nucleotide
1
2018
2275
0.020
Why?
Cause of Death
1
2010
273
0.020
Why?
Receptors, Androgen
1
2009
90
0.020
Why?
Quality of Life
1
2017
1387
0.020
Why?
Radiation Injuries
1
1990
158
0.020
Why?
Receptors, Tumor Necrosis Factor
1
2009
84
0.020
Why?
Thymidine
1
2008
58
0.020
Why?
Microarray Analysis
1
2009
93
0.020
Why?
Periodic Acid-Schiff Reaction
1
2008
6
0.020
Why?
Fluorescent Antibody Technique, Direct
1
2008
10
0.020
Why?
Pelvic Exenteration
1
2008
5
0.020
Why?
Data Interpretation, Statistical
1
2010
297
0.020
Why?
Perineum
1
2008
23
0.020
Why?
Intestinal Fistula
1
2008
30
0.020
Why?
Probability
1
2009
345
0.020
Why?
Lung Neoplasms
1
2020
2145
0.020
Why?
Amino Acid Sequence
2
2005
2077
0.020
Why?
Abdominal Cavity
1
2008
14
0.020
Why?
Antigens, Tumor-Associated, Carbohydrate
1
2007
11
0.020
Why?
Professional Practice
1
2008
43
0.020
Why?
Tomography, Emission-Computed
1
2008
104
0.020
Why?
Gastrointestinal Hemorrhage
1
1990
216
0.020
Why?
Gastric Outlet Obstruction
1
2007
11
0.020
Why?
Mice, Transgenic
2
2005
1514
0.020
Why?
Hospital Mortality
1
2010
323
0.020
Why?
Genes, bcl-2
1
2007
17
0.020
Why?
Caspase 7
1
2007
15
0.020
Why?
Cytochromes c
1
2007
27
0.020
Why?
Cyclin-Dependent Kinase 2
1
2007
23
0.020
Why?
Cholestasis
1
2007
44
0.020
Why?
Caspase 9
1
2007
47
0.020
Why?
Asthenia
1
2007
4
0.020
Why?
Cyclin-Dependent Kinase Inhibitor p27
1
2007
35
0.020
Why?
bcl-2-Associated X Protein
1
2007
46
0.020
Why?
Vagina
1
2008
102
0.020
Why?
Poly(ADP-ribose) Polymerases
1
2007
44
0.020
Why?
Growth Differentiation Factor 15
1
2007
9
0.020
Why?
Dactinomycin
1
2007
35
0.020
Why?
Intestinal Mucosa
1
1993
801
0.020
Why?
cdc25 Phosphatases
1
2006
17
0.020
Why?
Surgical Wound Dehiscence
1
1987
34
0.020
Why?
Workload
1
2008
125
0.020
Why?
Caspase 3
1
2007
160
0.020
Why?
Immunoglobulin G
1
2009
446
0.020
Why?
Xenograft Model Antitumor Assays
1
2008
442
0.020
Why?
CDC2 Protein Kinase
1
2006
44
0.020
Why?
Headache
1
2007
66
0.020
Why?
Cyclin B1
1
2006
16
0.020
Why?
Maleimides
1
2006
29
0.020
Why?
Mice, Knockout
1
2012
1909
0.020
Why?
Mitogen-Activated Protein Kinase 3
1
2006
68
0.020
Why?
Mitogen-Activated Protein Kinase 1
1
2006
74
0.020
Why?
MAP Kinase Kinase Kinases
1
2006
41
0.020
Why?
Vomiting
1
2008
182
0.020
Why?
Mice, Inbred BALB C
1
2008
1040
0.020
Why?
Positron-Emission Tomography
1
2007
273
0.020
Why?
Nitrobenzenes
1
2005
11
0.020
Why?
Cell Nucleus
1
2008
572
0.020
Why?
Nitrosamines
1
2005
8
0.020
Why?
Enzyme Activation
1
2007
692
0.020
Why?
Cyclooxygenase 2 Inhibitors
1
2005
35
0.020
Why?
Cell Growth Processes
1
2005
79
0.020
Why?
Electrophoresis, Polyacrylamide Gel
1
2005
275
0.020
Why?
Obesity, Morbid
1
2008
204
0.020
Why?
Androstadienes
1
2005
72
0.020
Why?
NIH 3T3 Cells
1
2005
104
0.020
Why?
Protein Kinase C
1
2006
270
0.020
Why?
Culture Media, Conditioned
1
2005
100
0.020
Why?
Coculture Techniques
1
2005
155
0.020
Why?
Base Sequence
2
1999
2326
0.020
Why?
Tumor Necrosis Factor-alpha
1
2009
679
0.020
Why?
Disease Management
1
2007
324
0.020
Why?
PPAR gamma
1
2005
63
0.020
Why?
Carcinogens
1
2005
108
0.020
Why?
RNA, Small Interfering
1
2007
539
0.020
Why?
Transfection
1
2007
892
0.020
Why?
Quinolines
1
2005
90
0.020
Why?
Random Allocation
1
2005
335
0.020
Why?
Neoplasm Transplantation
1
2005
388
0.020
Why?
Indoles
1
2006
317
0.020
Why?
Sequence Homology, Amino Acid
1
2005
418
0.020
Why?
Green Fluorescent Proteins
1
2005
296
0.020
Why?
Signal Transduction
2
2005
3162
0.020
Why?
Up-Regulation
1
2007
693
0.020
Why?
Pregnancy Complications
1
2007
328
0.020
Why?
Neoplasm Proteins
1
2007
531
0.020
Why?
Administration, Oral
1
2005
689
0.020
Why?
Sulfonamides
1
2005
297
0.020
Why?
Cell Survival
1
2006
958
0.020
Why?
Enzyme Inhibitors
1
2005
630
0.010
Why?
Transcription, Genetic
1
2007
1119
0.010
Why?
Protein Kinase Inhibitors
1
2006
556
0.010
Why?
Thyroid Gland
1
2002
265
0.010
Why?
Cell Line
1
2006
2474
0.010
Why?
Cell Differentiation
1
2007
1424
0.010
Why?
Vulvar Neoplasms
1
2000
19
0.010
Why?
Pregnancy
1
2007
2707
0.010
Why?
Technetium Tc 99m Sulfur Colloid
1
1999
10
0.010
Why?
Palpation
1
1999
18
0.010
Why?
Cells, Cultured
1
2005
2796
0.010
Why?
Coloring Agents
1
1999
65
0.010
Why?
Protein Isoforms
1
2000
259
0.010
Why?
Introns
1
2000
283
0.010
Why?
Blotting, Northern
1
1999
256
0.010
Why?
Axilla
1
1999
92
0.010
Why?
Radionuclide Imaging
1
1999
217
0.010
Why?
Exons
1
2000
441
0.010
Why?
Image Processing, Computer-Assisted
1
2005
1158
0.010
Why?
Medical Staff, Hospital
1
1999
108
0.010
Why?
Heart Failure
1
2007
1090
0.010
Why?
Proliferating Cell Nuclear Antigen
1
1997
64
0.010
Why?
Gynecomastia
1
1997
8
0.010
Why?
Mastectomy, Modified Radical
1
1997
6
0.010
Why?
Genetic Techniques
1
1997
70
0.010
Why?
Microscopy, Electron
1
1997
523
0.010
Why?
Recurrence
1
1999
1113
0.010
Why?
RNA, Double-Stranded
1
1996
22
0.010
Why?
Hyperplasia
1
1996
142
0.010
Why?
DEAD-box RNA Helicases
1
1996
57
0.010
Why?
eIF-2 Kinase
1
1995
46
0.010
Why?
Precancerous Conditions
1
1996
189
0.010
Why?
Ovarian Neoplasms
1
1993
675
0.000
Why?
Talamonti's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_